

Differentiation of Antigen-Specific T Cells with Limited Functional Capacity during *Mycobacterium tuberculosis* Infection

Yun Hee Jeong,^a Bo-Young Jeon,^b Sun-Hwa Gu,^b Sang-Nae Cho,^b Sung Jae Shin,^b Jun Chang,^c Sang-Jun Ha^a

Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, South Korea^a; Department of Microbiology, College of Medicine, Yonsei University, Seoul, South Korea^b; Division of Life and Pharmaceutical Sciences, College of Pharmacy, Ewha Woman's University, Seoul, South Korea^c

Despite the generation of *Mycobacterium tuberculosis*-specific T cell immune responses during the course of infection, only 5 to 10% of exposed individuals develop active disease, while others develop a latent infection. This phenomenon suggests defective *M. tuberculosis*-specific immunity, which necessitates more careful characterization of *M. tuberculosis*-specific T cell responses. Here, we longitudinally analyzed the phenotypes and functions of *M. tuberculosis*-specific T cells. In contrast to the functional exhaustion of T cells observed after chronic infection, *M. tuberculosis*-specific CD8⁺ T cells differentiated into either effector (CD127^{lo} CD62L^{lo}) or effector memory (CD127^{hi} CD62L^{lo}) cells, but not central memory cells (CD127^{hi} CD62L^{hi}), with low programmed death 1 (PD-1) expression, even in the presence of high levels of bacteria. Additionally, *M. tuberculosis*-specific CD8⁺ and CD4⁺ T cells produced substantial levels of tumor necrosis factor alpha (TNF- α) and gamma interferon (IFN- γ), but not interleukin 2 (IL-2), upon *in vitro* restimulation. Among *M. tuberculosis*-specific CD8⁺ T cells, CD127^{hi} effector memory cells displayed slower ongoing turnover but greater survival potential. In addition, these cells produced more IFN- γ and TNF- α and displayed lytic activity upon antigen stimulation. However, the effector function of *M. tuberculosis*-specific CD8⁺ CD127^{hi} effector memory T cells was inferior to that of canonical CD8⁺ CD127^{hi} memory T cells generated after acute lymphocytic choriomeningitis virus infection. Collectively, our data demonstrate that *M. tuberculosis*-specific T cells can differentiate into memory T cells during the course of *M. tuberculosis* infection independent of the bacterial burden but with limited functionality. These results provide a framework for further understanding the mechanisms of *M. tuberculosis* infection that can be used to develop more effective vaccines.

Mycobacterium tuberculosis is one of the most prevalent human pathogens, infecting 9.3 million people each year and leading to 1.3 million deaths (1). Because *M. tuberculosis* is a global health concern, the immune response against mycobacterial infection and the defensive mechanisms capable of mediating vaccine-induced protection have been studied intensively. *M. tuberculosis* is an intracellular pathogen that infects phagocytic antigen-presenting cells (APCs) in the lung. In these cells, *M. tuberculosis* survives in modified phagosomes and uses multiple mechanisms to evade both innate and adaptive host immunity, including perturbation of phagosome maturation, resistance to innate microbicidal activity and cytokine-mediated host defenses, and inhibition of antigen presentation (2). It has been well documented that a major protective immune response against *M. tuberculosis* is cell-mediated immunity (3, 4). In particular, T helper 1-type CD4⁺ T cells are pivotal for controlling the pathogenesis of *M. tuberculosis* (5–10). In contrast to CD4⁺ T cells, the role of CD8⁺ T cells in defense against the bacterium remains unclear. Many studies have shown that the kinetics of CD8⁺ and CD4⁺ T cell responses in the lung are identical and that similar changes in activation/memory phenotypes occur in pulmonary CD8⁺ and CD4⁺ T cells (11). β_2 -Microglobulin- or TAP1-deficient mice (12–14) and CD8⁺ T cell-depleted mice (10, 12) are more susceptible to *M. tuberculosis* infection than wild-type mice, indicating an essential role for CD8⁺ T cells in clearing the pathogen. In contrast, other studies have shown that CD8⁺ T cell depletion does not affect the bacterial load in the lungs of mice suffering from an acute *M. tuberculosis* infection (15). Therefore, the roles of CD4⁺ and CD8⁺ T cells in controlling *M. tuberculosis* infection are still being elucidated.

Memory T cells are important for mediating more effective

immune responses to pathogens. During most infections, 90 to 95% of antigen-specific CD8⁺ T cells that are generated by clonal expansion die after antigen clearance, and the surviving cells become the long-lived memory T cell population (16, 17). However, the surviving cells are not simply preformed memory CD8⁺ T cells constituting a minor population within the effector pool. These effector populations are identified by their expression of interleukin 7 receptor alpha (IL-7R α [CD127]) (18) and L-selectin (CD62L) (19); CD127^{hi} CD62L^{lo} subsets are classified as effector memory cells, and CD127^{hi} CD62L^{hi} subsets are classified as central memory cells. Studies have shown that CD127^{hi} CD62L^{lo} effector memory cells are more efficient producers of gamma interferon (IFN- γ) and tumor necrosis factor alpha (TNF- α) than CD127^{hi} CD62L^{hi} central memory cells, whereas interleukin 2 (IL-2) production is a property of central memory cells (19, 20). The development of memory T cells correlates inversely with repeated encounters with antigen (20, 21). Acute infections with viruses, such as influenza and vaccinia viruses, induce the differentiation of functional memory T cells in the absence of antigens

Received 17 April 2013 Returned for modification 13 May 2013

Accepted 7 October 2013

Published ahead of print 14 October 2013

Editor: J. L. Flynn

Address correspondence to Sang-Jun Ha, sjha@yonsei.ac.kr.

Supplemental material for this article may be found at <http://dx.doi.org/10.1128/IAI.00480-13>.

Copyright © 2014, American Society for Microbiology. All Rights Reserved.

doi:10.1128/IAI.00480-13

(22–24). In contrast, persisting viruses cause latent infection with periodic reactivation, such as with Epstein-Barr virus (25, 26), inducing functional T cells; smoldering infection with pockets of ongoing viral replication, inducing T cells with certain impaired effector functions, such as with cytomegalovirus (27–29); or chronic infection with viremia, inducing dysfunctional or exhausted T cells, as reported for a lymphocytic choriomeningitis virus (LCMV) model (30–32), human immunodeficiency virus (HIV) (33, 34), and hepatitis C virus (HCV) (35, 36).

Although most *M. tuberculosis* infections are asymptomatic and latent, approximately 1 in 10 latent infections eventually progresses to active disease. However, validated markers that indicate tuberculosis (TB) onset and correlate with protection against active disease have yet to be identified. In addition, the functional and phenotypic changes in *M. tuberculosis*-specific T cell immune responses in the lung during the course of infection have not been examined systematically. Therefore, in this study, we investigated longitudinally the differentiation and function of *M. tuberculosis*-specific T cells generated during *M. tuberculosis* infection. Our data provide fundamental insight that can be applied to the development of more effective vaccines against the bacterium.

MATERIALS AND METHODS

Mice. Specific-pathogen-free female C57BL/6 (B6) mice 5 to 6 weeks of age were purchased from Japan SLC, Inc., and maintained under barrier conditions in a biosafety level 3 (BSL-3) biohazard animal room at the Medical Research Center of Yonsei University College of Medicine. All experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of the College of Medicine, Yonsei University, and performed in accordance with the IACUC guidelines for the ethical use of animals.

Infection and counts. Mice were exposed to a predetermined dose of *M. tuberculosis* Erdman for 60 min in the inhalation chamber of an airborne-infection apparatus (Glas-Col, Terre Haute, IN, USA). The bacteria were counted 1 day after exposure, and approximately 200 to 300 viable *M. tuberculosis* bacteria were found to have been delivered to the lung. To enumerate the viable bacteria, the mice were euthanized with CO₂. The lung and spleen were homogenized in 0.04% Tween 80 in phosphate-buffered saline (PBS), and the tissue homogenates were serially diluted in PBS and plated in duplicate onto Middlebrook 7H11 agar (Difco). The colonies were counted after 3 to 4 weeks of incubation at 37°C, and the results are presented as the mean log₁₀ CFU per organ. For viral infections, mice were infected intraperitoneally (i.p.) with 2 × 10⁵ PFU of LCMV Armstrong (Arm) 53b, a triple-plaque-purified isolate of LCMV ARM CA1371 (37), which was obtained from Rafi Ahmed (Emory Vaccine Center, Atlanta, GA, USA).

Histopathology. For histopathological examination, the lungs were excised from all animals, stored in 10% formalin, and then embedded in paraffin at different times. From the paraffin-embedded tissue blocks, 2- to 3-μm sections were prepared and stained with hematoxylin and eosin (H&E). The H&E-stained lung sections were photographed using a microscope (Olympus Co.), and the level of inflammation in the lung was analyzed using the Image J program (National Institutes of Health, Bethesda, MD, USA).

Cell isolation. Lymphocytes from the lung and spleen were isolated as described previously (38). Briefly, each lung was perfused with ice-cold PBS before collection for lymphocyte isolation, chopped into small pieces, and incubated in RPMI supplemented with 1.3 mM EDTA at 37°C on a shaking incubator for 30 min. After the incubation, the small fragments were incubated again in complete medium solution containing 0.1% collagenase type II (Worthington Biochemical, Lakewood, NJ, USA) for 1 h. The lung lymphocytes were isolated by density gradient centrifugation by

underlying with 1× Percoll solution (Sigma-Aldrich, St. Louis, MO, USA).

In vitro stimulation assay. For CD8⁺ T cell stimulations, 1.5 × 10⁶ cells were incubated with ESAT-6₁₇₋₂₅ (AIQGNVTSI), Mtb32₉₃₋₁₀₂ (GAP INSATAM), TB10.4₃₋₁₁ (QIMYNYPPAM), Ag85A₂₋₁₁ (SRGLPVEYL), and Pst3S₂₈₅₋₂₉₃ (ISGVGNLDLV) peptides at 0.2 μg/ml for 6 h in the presence of brefeldin A and monensin.

For CD4⁺ T cell stimulations, the cells were incubated with a mixture of ESAT-6, Mtb32, TB10.4, Ag85A, and PstS3 peptides (1 μg/ml of each peptide). A total of 10, 33, 11, 29, and 33 peptides spanning the mature forms of ESAT-6, Mtb32, TB10.4, Ag85A, and PstS3, respectively, of *M. tuberculosis* were synthesized as 17- to 20-mer peptides that overlap by 10 amino acids.

For LCMV-specific T cell stimulation, lymphocytes were stimulated with 0.2 μg/ml of LCMV GP₃₃₋₄₁ peptide to induce a CD8⁺ T cell response and with 1.0 μg/ml of GP₆₆₋₈₀ peptide to induce a CD4⁺ T cell response. All peptides were synthesized by GenScript.

Antibodies and flow cytometry. To detect the expression of surface molecules on T cells, 1.5 × 10⁶ cells were stained with anti-CD4 (RM4-5), anti-CD8 (53-6.7), anti-CD44 (IM7), anti-CD62 L (MEL-14), anti-PD-1 (RMP1-30), and anti-CD127 (A7R34) antibodies. To measure the proliferation capability and apoptotic signal *ex vivo*, cells were stained with antibodies against Ki-67 (B56) and Bcl-2, respectively. D^bMtb32₉₃₋₁₀₂, K^bTB10.4₃₋₁₁, and D^bGP33₃₃₋₄₁ monomers conjugated to streptavidin-allophycocyanin (Invitrogen, Life Technologies, Carlsbad, CA, USA) were used to detect *M. tuberculosis*- and LCMV-specific CD8⁺ T cells. In the case of K^bTB10.4₃₋₁₁ staining, FASER-allophycocyanin activator (Miltenyi Biotec, Germany) was used to enhance the signal of TB10.4⁺ cells. For intracellular staining, antibodies against CD107a/b, TNF-α (MP6XT22), IL-2 (JES6-5H4), and IFN-γ (XMG1.2) were used in combination with anti-CD8 and anti-CD4 antibodies. The antibodies were purchased from eBioscience (San Diego, CA, USA), Biolegend (San Diego, CA, USA), and BD Biosciences (San Jose, CA, USA). All samples were acquired on FACSCalibur and FACSCantoII flow cytometers (BD Biosciences) and analyzed using FlowJo software (Tree Star, Ashland, OR, USA).

Statistical analysis. Statistical significance between groups was determined by the two-tailed unpaired Student's *t* test using Prism software version 5.02 (GraphPad, La Jolla, CA, USA).

RESULTS

Differentiation of *M. tuberculosis*-specific CD8⁺ T cells into memory cells during *M. tuberculosis* infection. To evaluate the host immune response to *M. tuberculosis* infection, we infected mice via aerosol exposure and then examined the numbers of viable bacilli over time. At 4 weeks following infection with 200 to 300 CFU of the virulent Erdman strain of *M. tuberculosis*, the bacterial burden in the lungs and spleen peaked. This level was maintained even in the late phase of infection (Fig. 1A). Histopathological changes in the lung tissues were observed from day 15 postinfection and rapidly increased from day 30 postinfection (see Fig. S1 in the supplemental material).

We next analyzed the immune response of *M. tuberculosis*-specific CD8⁺ T cells longitudinally by tetramer staining for D^b.Mtb32₉₃₋₁₀₂ and K^b.TB10.4₃₋₁₁-specific CD8⁺ T cells. The frequency of *M. tuberculosis*-specific CD8⁺ T cells increased progressively and appeared to be maintained for 5 to 9 weeks postinfection (Fig. 1B and C). All tetramer-positive CD8⁺ T cells expressed CD44, indicating that the cells were activated by T cell receptor (TCR) stimulation. The frequency of *M. tuberculosis*-specific CD8⁺ T cells in the spleen showed a similar pattern of kinetics, even though the frequency was much lower in the spleen than in the lung (see Fig. S2 in the supplemental material).

To more carefully investigate *M. tuberculosis*-specific CD8⁺ T




FIG 1 Kinetics of *M. tuberculosis*-specific CD8⁺ T cells in the lung during *M. tuberculosis* infection. Lung lymphocytes were isolated at the indicated time points after initial infection with *M. tuberculosis*. (A) Kinetics of *M. tuberculosis* Erdman growth in the lungs of C57BL/6 mice infected aerogenically with 300 CFU bacilli. The bacterial burden in the lungs was assessed at the indicated times. (B) D^bMtb32₉₃₋₁₀₂- and K^bTB10.4₃₋₁₁-specific CD8⁺ T cells were identified by tetramer staining. The numbers in the plots represent the percentages of tetramer-positive cells among CD8⁺ T cells. d, day(s). (C) The absolute numbers of D^bMtb32₉₃₋₁₀₂- and K^bTB10.4₃₋₁₁-specific CD8⁺ T cells in the lung were calculated. The graphs show the means ± standard errors of the mean (SEM). The data are representative of at least two independent experiments ($n = 3$ or 4 at each time point).

cells at the infection site, the phenotypes of both D^bMtb32₉₃₋₁₀₂- and K^bTB10.4₃₋₁₁-specific CD8⁺ T cells in the lung were characterized by staining with canonical markers commonly used to discriminate between effector and memory T cells (Fig. 2A and B; see Fig. S2A and B in the supplemental material). *M. tuberculosis*-specific CD8⁺ T cells rapidly downregulated both CD127 and CD62L expression by day 15 postinfection. Interestingly, the expression of CD127 on *M. tuberculosis*-specific CD8⁺ T cells seemed to be restored progressively, unlike CD62L expression. These results indicate that a substantial population of *M. tuberculosis*-specific CD8⁺ T cells at the infection site differentiated from an effector (CD127^{lo} CD62L^{lo}) to an effector memory (CD127^{hi} CD62L^{lo}) phenotype over the course of infection. Meanwhile, the expression of programmed death 1 (PD-1) on *M. tuberculosis*-specific CD8⁺ T cells was induced temporarily by day 15 postinfection, as its expression was downregulated thereafter (Fig. 2C and D; see Fig. S3C in the supplemental material). Taken together, these results demonstrate that *M. tuberculosis*-specific CD8⁺ T cells differentiate into an effector memory, but not central memory, phenotype even after the late phase of *M. tuberculosis* infection.

Functional capacity of *M. tuberculosis*-specific T cells during *M. tuberculosis* infection. Although large numbers of *M. tuberculosis*-specific CD8⁺ T cells were generated postinfection, the bacterial growth was not controlled. Therefore, we assessed whether *M. tuberculosis*-specific CD8⁺ T cells are capable of producing effector cytokines at the single-cell level. To address this, we performed a kinetic analysis of CD8⁺ T cell function. Interestingly, upon *in vitro* restimulation with the Mtb32₉₃₋₁₀₂, TB10.4₃₋₁₁, and ESAT-6₁₇₋₂₅ peptides, we observed a substantial increase in TNF-α and IFN-γ coproducers among the IFN-γ-producing CD8⁺ T cell population at day 30 postinfection compared with the number of coproducers at day 15 postinfection (Fig. 3A and B). In the case of Mtb32₉₃₋₁₀₂ stimulation, the percentage of dual-cytokine producers among IFN-γ-producing CD8⁺ T cells gradually decreased after day 30. In contrast, TB10.4- and ESAT-6-specific CD8⁺ T cells continued to produce both TNF-α and IFN-γ until a late time point.

Next, we assessed the functionality of CD4⁺ and CD8⁺ T cells specific to various *M. tuberculosis* antigens in the late phase of infection. We investigated the capacity of *M. tuberculosis*-specific CD8⁺ and CD4⁺ T cells to produce IL-2 and IFN-γ at day 100 postinfection. Interestingly, a very limited population of IFN-γ-producing CD8⁺ T cells produced IL-2 upon stimulation with various *M. tuberculosis* peptides (Fig. 3C, left). The percentage of IFN-γ-producing CD8⁺ T cells varied according to the specific antigenic peptide (Fig. 3D), but the percentage of IL-2 and IFN-γ producers among them was below 15% for various *M. tuberculosis* antigen-specific CD8⁺ T cells (Fig. 3E). This phenomenon was also observed in the spleen (see Fig. S4 in the supplemental material). To analyze the functionality of CD4⁺ T cells specific to *M. tuberculosis*, the cells were stimulated with a pool of the various *M. tuberculosis* antigens (Fig. 3C, right). Whereas *M. tuberculosis*-specific CD8⁺ T cells responded to the different antigens, CD4⁺ T cells primarily responded to ESAT-6 and produced a substantial level of IFN-γ (Fig. 3D). These results suggest that ESAT-6 contains the dominant CD4⁺-specific epitope. Similar to *M. tuberculosis*-specific CD8⁺ T cells, ESAT-6-specific CD4⁺ T cells could produce only a limited amount of IL-2 (Fig. 3E). These data demonstrate that *M. tuberculosis*-specific CD8⁺ and CD4⁺ T cells can produce both IFN-γ and TNF-α upon antigen stimulation but are very limited in their capacity to produce IL-2.

Different functional capacities of effector and effector memory subsets during *M. tuberculosis* infection. We found that *M. tuberculosis*-specific CD8⁺ T cells did not differentiate into central memory cells. Instead, they maintained an effector or effector memory phenotype, namely, CD127^{lo} CD62L^{lo} or CD127^{hi} CD62L^{lo}, respectively. These cells produced IFN-γ and TNF-α abundantly but generated only limited quantities of IL-2. To compare the functional properties of these two CD8⁺ T cell populations during *M. tuberculosis* infection, Mtb32-specific CD8⁺ T cells isolated from *M. tuberculosis*-infected mice at day 60 postinfection were examined for the expression of CD127, along with various functional markers (e.g., Bcl-2, Ki-67, and CD107a/b) and cytokine production. As a control representing a typical memory CD8⁺ T cell, we used LCMV glycoprotein (GP) 33-41 epitope-specific CD8⁺ T cells isolated from LCMV Arm-infected mice at day 60 postinfection, which is when LCMV-specific CD8⁺ T cells differentiate into effector or central memory T cells. First, we examined the ongoing turnover status of *M. tuberculosis*-specific CD8⁺ T cells by measuring *ex vivo* the expression of Ki-67 (a




FIG 2 Phenotypic changes in *M. tuberculosis*-specific CD8⁺ T cells in the lung during *M. tuberculosis* infection. Lung lymphocytes were isolated at the indicated time points after initial infection with *M. tuberculosis*. (A) After gating for CD8⁺ T cells, the coexpression of CD127 and CD62L was analyzed for D^bMtb32₉₃₋₁₀₂ (top) and K^bTB10.4₃₋₁₁ (bottom) tetramer-positive cells. The plot at day 0 represents naive CD8⁺ T cells. The numbers in the plots indicate the percentages of CD127⁺ CD62L⁺ (central memory) and CD127⁺ CD62L⁻ (effector memory) cells. (B) Summary of the kinetic analysis in panel A for the percentages of CD127^{hi} tetramer-positive cells at the indicated time points after initial *M. tuberculosis* infection. (C) After gating for CD8⁺ T cells, the coexpression of CD44 and PD-1 was analyzed for D^bMtb32₉₃₋₁₀₂ (top) and K^bTB10.4₃₋₁₁ (bottom) tetramer-positive cells. The plot at day 0 represents naive CD8⁺ T cells. (D) Summary of the mean fluorescence intensities (MFI) of PD-1 on the tetramer-positive CD8⁺ T cells at the indicated time points after initial *M. tuberculosis* infection. The graphs show the means ± SEM. The data are representative of at least two independent experiments (*n* = 3 or 4 at each time point).

marker of recently proliferated cells). Among *M. tuberculosis*-specific CD8⁺ T cells, CD127^{lo} effector T cells expressed a significantly higher level of Ki-67 than CD127^{hi} effector memory T cells (Fig. 4A). As expected, LCMV-specific memory T cells did not

express Ki-67. Next, we examined the survival ability of these cells by measuring the expression level of Bcl-2, a marker of anti-apoptosis. The level of Bcl-2 in CD127^{hi} effector memory cells was significantly higher than that in CD127^{lo} effector cells (Fig. 4A).




FIG 3 Functional changes in *M. tuberculosis*-specific CD8⁺ T cells in the lung during *M. tuberculosis* infection. Lung lymphocytes were isolated at the indicated time points after initial infection with *M. tuberculosis* and then restimulated *in vitro* with Mtb32₉₃₋₁₀₂, TB10.4₃₋₁₁, or ESAT6₁₇₋₂₅ peptide. (A) Representative data showing the percentages of cytokine-producing cells among the CD8⁺ T cells. The numbers in red depict the percentages of IFN- γ and TNF- α coproducers among IFN- γ -producing cells. (B) Summary showing the frequencies of TNF- α -producing cells among the IFN- γ ⁺ CD8⁺ or IFN- γ ⁺ CD4⁺ T cells. At day 100 postinfection, CD8⁺ T cells were stimulated with Mtb32, TB10.4, ESAT-6, Ag85A, or PstS3 peptide, while CD4⁺ T cells were stimulated with a pool containing all the peptides (see Materials and Methods). The numbers in red indicate the percentages of IFN- γ and IL-2 coproducers among the IFN- γ -producing cells. (D) Summary showing the total percentages of IFN- γ -producing cells according to peptide stimulation. (E) Summary of the percentages of IL-2-coproducing cells among the total IFN- γ ⁺ population according to peptide stimulation. The graphs show the means ± SEM. The data are representative of at least two independent experiments (*n* = 3 or 4 at each time point).




FIG 4 Different functional properties of effector and effector memory T cell subsets during *M. tuberculosis* infection. (A) Lung lymphocytes were isolated at day 60 after *M. tuberculosis* and LCMV Arm infection. D^bMtb32₉₃₋₁₀₂- and D^bGP33₃₃₋₄₁-specific CD8⁺ T cells were identified by tetramer staining. Tetramer-positive cells were divided into effector (red boxes) and effector memory (gray boxes) populations based on CD127 expression. The percentages of Ki-67⁺ cells in CD127^{hi} (red) and CD127^{lo} (gray) cells are depicted at the top and summarized on the right. The MFI levels of Bcl-2 on CD127^{hi} (red) and CD127^{lo} (gray) populations are shown at the top. (B) Lung lymphocytes were restimulated *in vitro* with Mtb32₉₃₋₁₀₂ and GP33₃₃₋₄₁. After gating for CD8⁺ T cells, IFN- γ ⁺ cells were divided into effector (gray bar) and effector memory (red bar) populations based on CD127 expression. The histogram represents the levels of IFN- γ , TNF- α , and CD107a/b expressed in IFN- γ ⁺ effector (gray lines) and effector memory (red lines) cells. The numbers in the plots represent the MFI (black for effector cells and red for effector memory cells), which is also summarized in bar graphs (below) as the means and SEM. The *P* values, determined by the Student *t* test, are indicated as follows: *, *P* < 0.05; **, *P* < 0.01; and ***, *P* < 0.001 (*n* = 4 per group).

LCMV-specific memory T cells, however, showed the highest level of Bcl-2 expression. Overall, the CD127^{hi} effector memory population in *M. tuberculosis*-specific CD8⁺ T cells displayed a lower ongoing turnover rate that was more sustainable than that of the CD127^{lo} effector population.

We also compared the abilities of *M. tuberculosis*-specific CD127^{hi} and CD127^{lo} CD8⁺ T cells to produce IFN- γ and TNF- α , as well as their capacities to acquire lytic activity upon antigen stimulation (Fig. 4B). Upon Mtb32 peptide stimulation, CD127^{hi} effector memory CD8⁺ T cells produced more IFN- γ and TNF- α . Furthermore, these cells showed a higher level of degranulation than CD127^{lo} effector CD8⁺ T cells. CD8⁺ T cells specific for TB10.4-specific CD127^{hi} and CD127^{lo} CD8⁺ T cells also showed similar response patterns (see Fig. S5 in the supplemental material). However, the effector function of *M. tuberculosis*-specific CD8⁺ CD127^{hi} effector memory T cells was inferior to that of LCMV-specific CD8⁺ CD127^{hi} memory T cells, suggesting the functional limitation of *M. tuberculosis*-specific memory CD8⁺ T cells compared to typical memory CD8⁺ T cells.

DISCUSSION

In this study, we characterized the longitudinal T cell immune response to *M. tuberculosis* infection. Although many studies have investigated this response, there is little information about its

overall kinetics and the functional properties of *M. tuberculosis*-specific CD8⁺ T cell populations during the course of infection. Here, we found that *M. tuberculosis*-specific CD8⁺ T cells were capable of differentiating into a canonical effector memory state with a CD127^{hi} CD62L^{lo} PD-1^{lo} phenotype. It has been generally known that effector memory CD8⁺ T cells gradually convert into central memory CD8⁺ T cells. However, this differentiation did not occur in the spleens or lungs of *M. tuberculosis*-infected mice even during the late phase of infection, which limited the cells' capacity to produce IL-2. In addition, when we compared the functional properties of the CD127^{hi} CD62L^{lo} effector memory population with those of the CD127^{lo} CD62L^{lo} effector population within *M. tuberculosis*-specific CD8⁺ T cells, effector memory cells displayed slower ongoing turnover but greater survival potential and cytokine production than effector cells. In summary, our study provides an overview of *M. tuberculosis*-specific CD8⁺ T cell immune responses at the site of *M. tuberculosis* infection over time.

Because T helper 1-type CD4⁺ T cells are crucial for protection against *M. tuberculosis*, the frequency of IFN- γ -producing CD4⁺ T cells has been widely used as an indicator of this response. However, gauging the magnitude of T cell responses by a single parameter, such as IFN- γ production, may not reflect *M. tuberculosis*-specific immune responses and defense against the bacterium.

Recently, it was found that the polyfunctional profiles (IFN- γ^+ IL-2 $^+$ TNF- α^+) of antigen-specific T cell responses are related to disease activity during *M. tuberculosis* infection (39, 40). Interestingly, the frequency of CD4 $^+$ T cells producing TNF- α , but not IFN- γ and IL-2, was reported to be the strongest predictor of a diagnosis of active TB or latent infection (41). In our report, we found a very limited population of cells with an IFN- γ^+ IL-2 $^+$ profile upon stimulation with various *M. tuberculosis* peptides, suggesting that this limitation only partially contributes to a persistent infection. This incomplete functional capacity of *M. tuberculosis*-specific T cells seems to be related to the cells' effector memory phenotype (CD127 $^{\text{hi}}$ CD62L $^{\text{lo}}$), because the cells do not efficiently produce IL-2 compared with central memory T cells (19, 20).

Among the various inhibitory receptors, PD-1 is a phenotypic hallmark of functionally impaired T cells generated during chronic pathogen infection (38, 42–45). The interaction between PD-1 and its ligand, PD-L1, has been demonstrated to inhibit TCR signaling, causing the deterioration of T cell immune responses to human viruses, including HBV, HCV, and HIV (46–50). Interestingly, despite multiple studies of viral infection that demonstrate PD-1 as a reliable marker of exhaustion, previous studies reported the susceptibility phenotype of PD-1 knockout (KO) mice during *M. tuberculosis* infection (51, 52). Reiley et al. showed that PD-1-expressing T cells proliferate and are functionally active rather than exhausted, thus representing a precursor population of antigen-specific T cells (53). Consistent with these reports, we observed that PD-1-expressing *M. tuberculosis*-specific CD8 $^+$ T cells produce the effector cytokines IFN- γ and TNF- α and do not appear to be exhausted (Fig. 3A). Therefore, our results indicate that PD-1 is not a marker of chronically exhausted T cells during *M. tuberculosis* infection.

Even though the level of PD-1 has been reported to correlate with antigen presence (54), our study showed that PD-1 expression on *M. tuberculosis*-specific CD8 $^+$ T cells was temporary, reaching a peak at day 15 postinfection and then decreasing progressively after day 30, when the bacterial burden had peaked. This observation could be caused by differences in the anatomical localization of *M. tuberculosis*-specific CD8 $^+$ T cells and their potential responder cells, APCs, which present *M. tuberculosis* antigens. During the course of aerosol infection with *M. tuberculosis*, a granuloma consisting of various immune cells, including APCs, forms. This hallmark of TB develops in the lung after 4 to 5 weeks of infection. In general, bacteria are most commonly present in the central area of the granuloma (55). In contrast to APCs harboring *M. tuberculosis* or other, related antigens, *M. tuberculosis*-specific T cells rarely enter the central region of the granuloma and instead localize to peripheral regions (55). Therefore, the progressive loss of PD-1 expression by *M. tuberculosis*-specific CD8 $^+$ T cells may be caused by their reduced opportunity to interact with APCs presenting *M. tuberculosis* antigens due to differences in their localization. Collectively, we showed that PD-1 expression on antigen-specific T cells does not always correlate with the pathogen titer, suggesting that PD-1 is not a marker for the bacterial burden in the case of *M. tuberculosis* infection.

The generation of different subsets of *M. tuberculosis*-specific CD8 $^+$ T cells, namely, CD127 $^{\text{hi}}$ CD62L $^{\text{lo}}$ effector memory or CD127 $^{\text{lo}}$ CD62L $^{\text{lo}}$ effector populations, during *M. tuberculosis* infection may also be affected by differences in localization within the lung and/or frequency of interaction with APCs. Some *M.*

tuberculosis-specific CD8 $^+$ T cells may have little opportunity to contact antigens and subsequently differentiate into effector memory T cells, whereas other *M. tuberculosis*-specific CD8 $^+$ T cells may contact antigens more frequently and remain as effector T cells. This hypothesis is supported by our observation that CD127 $^{\text{hi}}$ effector memory cells displayed a slower ongoing turnover status than CD127 $^{\text{lo}}$ effector cells because rapidly proliferating CD8 $^+$ T cells, which express Ki-67, are dependent on antigen presentation.

Although the current vaccine against TB, *Mycobacterium bovis* bacillus Calmette-Guérin, is effective in protecting children from the disease, it does not induce consistent protection against adult TB. Meanwhile, the precise immune mechanisms of protection remain incompletely understood. Therefore, we need to understand the basic immunology underlying *M. tuberculosis* infection and to develop a TB vaccine with better efficacy. In this study, we have characterized the functional effector memory state of CD8 $^+$ and CD4 $^+$ T cells during *M. tuberculosis* infection and demonstrated that these functional effector memory populations increased upon infection. However, effector T cells may be physically restricted from contacting APCs by the granuloma, thereby delaying their differentiation. Overall, the results from this study provide information about the longitudinal immune response that can be applied to the development of better vaccines.

ACKNOWLEDGMENT

This study was supported by a grant from the Korean Health Technology R&D Project, Ministry for Health, Welfare and Family Affairs, and the Republic of Korea (A101750).

REFERENCES

1. Dye C, Williams BG. 2010. The population dynamics and control of tuberculosis. *Science* 328:856–861. <http://dx.doi.org/10.1126/science.1185449>.
2. Harding CV, Boom WH. 2010. Regulation of antigen presentation by *Mycobacterium tuberculosis*: a role for Toll-like receptors. *Nat. Rev. Microbiol.* 8:296–307. <http://dx.doi.org/10.1038/nrmicro2321>.
3. Kaufmann SH. 1995. Immunity to intracellular microbial pathogens. *Immunol. Today* 16:338–342. [http://dx.doi.org/10.1016/0167-5699\(95\)80151-0](http://dx.doi.org/10.1016/0167-5699(95)80151-0).
4. Leveton C, Barnass S, Champion B, Lucas S, De Souza B, Nicol M, Banerjee D, Rook G. 1989. T-cell-mediated protection of mice against virulent *Mycobacterium tuberculosis*. *Infect. Immun.* 57:390–395.
5. Saunders BM, Frank AA, Orme IM, Cooper AM. 2002. CD4 is required for the development of a protective granulomatous response to pulmonary tuberculosis. *Cell Immunol.* 216:65–72. [http://dx.doi.org/10.1016/S0008-8749\(02\)00510-5](http://dx.doi.org/10.1016/S0008-8749(02)00510-5).
6. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. 1993. Disseminated tuberculosis in interferon gamma gene-disrupted mice. *J. Exp. Med.* 178:2243–2247. <http://dx.doi.org/10.1084/jem.178.6.2243>.
7. Cooper AM, Flynn JL. 1995. The protective immune response to *Mycobacterium tuberculosis*. *Curr. Opin. Immunol.* 7:512–516. [http://dx.doi.org/10.1016/0952-7915\(95\)80096-4](http://dx.doi.org/10.1016/0952-7915(95)80096-4).
8. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. 1993. An essential role for interferon gamma in resistance to *Mycobacterium tuberculosis* infection. *J. Exp. Med.* 178:2249–2254. <http://dx.doi.org/10.1084/jem.178.6.2249>.
9. Caruso AM, Serbina N, Klein E, Triebold K, Bloom BR, Flynn JL. 1999. Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. *J. Immunol.* 162:5407–5416.
10. Mogues T, Goodrich ME, Ryan L, LaCourse R, North RJ. 2001. The relative importance of T cell subsets in immunity and immunopathology of airborne *Mycobacterium tuberculosis* infection in mice. *J. Exp. Med.* 193:271–280. <http://dx.doi.org/10.1084/jem.193.3.271>.
11. Feng CG, Bean AG, Hooi H, Briscoe H, Britton WJ. 1999. Increase in gamma interferon-secreting CD8(+), as well as CD4(+), T cells in lungs

- following aerosol infection with *Mycobacterium tuberculosis*. *Infect. Immun.* 67:3242–3247.
12. Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR. 1992. Major histocompatibility complex class I-restricted T cells are required for resistance to *Mycobacterium tuberculosis* infection. *Proc. Natl. Acad. Sci. U. S. A.* 89:12013–12017. <http://dx.doi.org/10.1073/pnas.89.24.12013>.
 13. Muller I, Cobbold SP, Waldmann H, Kaufmann SH. 1987. Impaired resistance to *Mycobacterium tuberculosis* infection after selective in vivo depletion of L3T4+ and Lyt-2+ T cells. *Infect. Immun.* 55:2037–2041.
 14. Orme IM. 1987. The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with *Mycobacterium tuberculosis*. *J. Immunol.* 138:293–298.
 15. van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P. 2000. Control of latent *Mycobacterium tuberculosis* infection is dependent on CD8 T cells. *Eur. J. Immunol.* 30:3689–3698. [http://dx.doi.org/10.1002/1521-4141\(200012\)30:12<3689::AID-IMMU3689>3.0.CO;2-4](http://dx.doi.org/10.1002/1521-4141(200012)30:12<3689::AID-IMMU3689>3.0.CO;2-4).
 16. Busch DH, Pilip IM, Vijn S, Pamer EG. 1998. Coordinate regulation of complex T cell populations responding to bacterial infection. *Immunity* 8:353–362. [http://dx.doi.org/10.1016/S1074-7613\(00\)80540-3](http://dx.doi.org/10.1016/S1074-7613(00)80540-3).
 17. Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ, Zajac AJ, Miller JD, Slansky J, Ahmed R. 1998. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. *Immunity* 8:177–187. [http://dx.doi.org/10.1016/S1074-7613\(00\)80470-7](http://dx.doi.org/10.1016/S1074-7613(00)80470-7).
 18. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. 2003. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. *Nat. Immunol.* 4:1191–1198. <http://dx.doi.org/10.1038/ni1009>.
 19. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature* 401:708–712. <http://dx.doi.org/10.1038/44385>.
 20. Wherry EJ, Ahmed R. 2004. Memory CD8 T-cell differentiation during viral infection. *J. Virol.* 78:5535–5545. <http://dx.doi.org/10.1128/JVI.78.11.5535-5545.2004>.
 21. Kaech SM, Wherry EJ, Ahmed R. 2002. Effector and memory T-cell differentiation: implications for vaccine development. *Nat. Rev. Immunol.* 2:251–262. <http://dx.doi.org/10.1038/nri778>.
 22. Demkowicz WE, Jr, Littau RA, Wang J, Ennis FA. 1996. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. *J. Virol.* 70:2627–2631.
 23. Lavani A, Brookes R, Hambleton S, Britton WJ, Hill AV, McMichael AJ. 1997. Rapid effector function in CD8+ memory T cells. *J. Exp. Med.* 186:859–865. <http://dx.doi.org/10.1084/jem.186.6.859>.
 24. Hammarlund E, Lewis MW, Hansen SG, Strelow LJ, Nelson JA, Sexton GJ, Hanifin JM, Slifka MK. 2003. Duration of antiviral immunity after smallpox vaccination. *Nat. Med.* 9:1131–1137. <http://dx.doi.org/10.1038/nm917>.
 25. Callan MF. 2003. The evolution of antigen-specific CD8+ T cell responses after natural primary infection of humans with Epstein-Barr virus. *Viral Immunol.* 16:3–16. <http://dx.doi.org/10.1089/088282403763635401>.
 26. Rickinson AB, Moss DJ. 1997. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. *Annu. Rev. Immunol.* 15:405–431. <http://dx.doi.org/10.1146/annurev.immunol.15.1.405>.
 27. Sissons JG, Carmichael AJ, McKinney N, Sinclair JH, Wills MR. 2002. Human cytomegalovirus and immunopathology. *Springer Semin. Immunopathol.* 24:169–185. <http://dx.doi.org/10.1007/s00281-002-0104-0>.
 28. Gillespie GM, Wills MR, Appay V, O'Callaghan C, Murphy M, Smith N, Sissons P, Rowland-Jones S, Bell JI, Moss PA. 2000. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. *J. Virol.* 74:8140–8150. <http://dx.doi.org/10.1128/JVI.74.17.8140-8150.2000>.
 29. Sandberg JK, Fast NM, Nixon DF. 2001. Functional heterogeneity of cytokines and cytolytic effector molecules in human CD8+ T lymphocytes. *J. Immunol.* 167:181–187.
 30. Fuller MJ, Zajac AJ. 2003. Ablation of CD8 and CD4 T cell responses by high viral loads. *J. Immunol.* 170:477–486.
 31. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. 2003. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. *J. Virol.* 77:4911–4927. <http://dx.doi.org/10.1128/JVI.77.8.4911-4927.2003>.
 32. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, Ahmed R. 1998. Viral immune evasion due to persistence of activated T cells without effector function. *J. Exp. Med.* 188:2205–2213. <http://dx.doi.org/10.1084/jem.188.12.2205>.
 33. Goepfert PA, Bansal A, Edwards BH, Ritter GD, Jr, Tellez I, McPherson SA, Sabbaj S, Mulligan MJ. 2000. A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon. *J. Virol.* 74:10249–10255. <http://dx.doi.org/10.1128/JVI.74.21.10249-10255.2000>.
 34. Kostense S, Ogg GS, Manting EH, Gillespie G, Joling J, Vandenbergh K, Veenhof EZ, van Baarle D, Jurriaans S, Klein MR, Miedema F. 2001. High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function. *Eur. J. Immunol.* 31:677–686. [http://dx.doi.org/10.1002/1521-4141\(200103\)31:3<677::AID-IMMU677>3.0.CO;2-M](http://dx.doi.org/10.1002/1521-4141(200103)31:3<677::AID-IMMU677>3.0.CO;2-M).
 35. Gruener NH, Lechner F, Jung MC, Diepolder H, Gerlach T, Lauer G, Walker B, Sullivan J, Phillips R, Pape GR, Klenerman P. 2001. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. *J. Virol.* 75:5550–5558. <http://dx.doi.org/10.1128/JVI.75.12.5550-5558.2001>.
 36. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips R, Klenerman P, Walker BD. 2000. Analysis of successful immune responses in persons infected with hepatitis C virus. *J. Exp. Med.* 191:1499–1512. <http://dx.doi.org/10.1084/jem.191.9.1499>.
 37. Dutko FJ, Oldstone MB. 1983. Genomic and biological variation among commonly used lymphocytic choriomeningitis virus strains. *J. Gen. Virol.* 64:1689–1698. <http://dx.doi.org/10.1099/0022-1317-64-8-1689>.
 38. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature* 439:682–687. <http://dx.doi.org/10.1038/nature04444>.
 39. Forbes EK, Sander C, Ronan EO, McShane H, Hill AV, Beverley PC, Tchilian EZ. 2008. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against *Mycobacterium tuberculosis* aerosol challenge in mice. *J. Immunol.* 181:4955–4964.
 40. Mittrucker HW, Steinhoff U, Kohler A, Krause M, Lazar D, Mex P, Miekley D, Kaufmann SH. 2007. Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. *Proc. Natl. Acad. Sci. U. S. A.* 104:12434–12439. <http://dx.doi.org/10.1073/pnas.0703510104>.
 41. Harari A, Rozot V, Enders FB, Perreau M, Stalder JM, Nicod LP, Cavassini M, Calandra T, Blanchet CL, Jaton K, Faouzi M, Day CL, Hanekom WA, Bart PA, Pantaleo G. 2011. Dominant TNF-alpha+ *Mycobacterium tuberculosis*-specific CD4+ T cell responses discriminate between latent infection and active disease. *Nat. Med.* 17:372–376. <http://dx.doi.org/10.1038/nm.2299>.
 42. Ha SJ, Mueller SN, Wherry EJ, Barber DL, Aubert RD, Sharpe AH, Freeman GJ, Ahmed R. 2008. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. *J. Exp. Med.* 205:543–555. <http://dx.doi.org/10.1084/jem.20071949>.
 43. Jin HT, Jeong YH, Park HJ, Ha SJ. 2011. Mechanism of T cell exhaustion in a chronic environment. *BMB Rep.* 44:217–231. <http://dx.doi.org/10.5483/BMBRep.2011.44.4.217>.
 44. Virgin HW, Wherry EJ, Ahmed R. 2009. Redefining chronic viral infection. *Cell* 138:30–50. <http://dx.doi.org/10.1016/j.cell.2009.06.036>.
 45. Wherry EJ. 2011. T cell exhaustion. *Nat. Immunol.* 12:492–499. <http://dx.doi.org/10.1038/ni.2035>.
 46. Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, Missale G, Ferrari C. 2006. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. *J. Virol.* 80:11398–11403. <http://dx.doi.org/10.1128/JVI.01177-06>.
 47. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. *Nature* 443:350–354. <http://dx.doi.org/10.1038/nature05115>.
 48. Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, Adams WC, Precoipio ML, Schacker T, Roederer M, Douek DC, Koup RA. 2006. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. *J. Exp. Med.* 203:2281–2292. <http://dx.doi.org/10.1084/jem.20061496>.
 49. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, Boulassel MR, Delwart E, Sepulveda H, Balderas RS, Routy JP, Haddad EK, Sekaly RP. 2006. Upregulation of PD-1 expression on HIV-specific

- CD8+ T cells leads to reversible immune dysfunction. *Nat. Med.* 12: 1198–1202. <http://dx.doi.org/10.1038/nm1482>.
50. Boni C, Fiscaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G, Bertoletti A, Ferrari C. 2007. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. *J. Virol.* 81:4215–4225. <http://dx.doi.org/10.1128/JVI.02844-06>.
 51. Lazar-Molnar E, Chen B, Sweeney KA, Wang EJ, Liu W, Lin J, Porcelli SA, Almo SC, Nathenson SG, Jacobs WR, Jr. 2010. Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. *Proc. Natl. Acad. Sci. U. S. A.* 107:13402–13407. <http://dx.doi.org/10.1073/pnas.1007394107>.
 52. Barber DL, Mayer-Barber KD, Feng CG, Sharpe AH, Sher A. 2011. CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition. *J. Immunol.* 186:1598–1607. <http://dx.doi.org/10.4049/jimmunol.1003304>.
 53. Reiley WW, Shafiani S, Wittmer ST, Tucker-Heard G, Moon JJ, Jenkins MK, Urdahl KB, Winslow GM, Woodland DL. 2010. Distinct functions of antigen-specific CD4 T cells during murine *Mycobacterium tuberculosis* infection. *Proc. Natl. Acad. Sci. U. S. A.* 107:19408–19413. <http://dx.doi.org/10.1073/pnas.1006298107>.
 54. Adekambi T, Ibegbu CC, Kalokhe AS, Yu T, Ray SM, Rengarajan J. 2012. Distinct effector memory CD4+ T cell signatures in latent *Mycobacterium tuberculosis* infection, BCG vaccination and clinically resolved tuberculosis. *PLoS One* 7:e36046. <http://dx.doi.org/10.1371/journal.pone.0036046>.
 55. Ramakrishnan L. 2012. Revisiting the role of the granuloma in tuberculosis. *Nat. Rev. Immunol.* 12:352–366. <http://dx.doi.org/10.1038/nri3211>.

AUTHOR CORRECTION

Differentiation of Antigen-Specific T Cells with Limited Functional Capacity during *Mycobacterium tuberculosis* Infection

Yun Hee Jeong,^a Bo-Young Jeon,^b Sun-Hwa Gu,^b Sang-Nae Cho,^b Sung Jae Shin,^b Jun Chang,^c Sang-Jun Ha^a

Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, South Korea^a; Department of Microbiology, College of Medicine, Yonsei University, Seoul, South Korea^b; Division of Life and Pharmaceutical Sciences, College of Pharmacy, Ewha Woman's University, Seoul, South Korea^c

Volume 82, no. 1, p. 132–139, 2014. Page 137, column 2: The Acknowledgment should read “This study was supported by grants from the Korean Health Technology R&D Project, Ministry for Health, Welfare and Family Affairs, and the Republic of Korea (A101750 and HI13C0833).”